LabCorp 2015 Annual Report Download - page 47

Index
 
The selected financial data presented below under the captions “Statement of Operations Data” and “Balance Sheet Data” as of and for the five-year
period ended December 31, 2015 are derived from consolidated financial statements of the Company, which have been audited by an independent registered
public accounting firm. This data should be read in conjunction with the accompanying notes, the Company's consolidated financial statements and the
related notes thereto, and “Management's Discussion and Analysis of Financial Condition and Results of Operations,” all included elsewhere herein.
 










 
:
Net revenues $ 8,505.7
$ 6,011.6
$ 5,808.3
$ 5,671.4
$ 5,542.3
Gross profit 2,903.3
2,203.1
2,223.2
2,249.7
2,274.7
Operating income 1,002.9
910.4
990.9
1,023.5
948.4
Net earnings attributable to Laboratory
Corporation of America Holdings 436.9
511.2
573.8
583.1
519.7
Basic earnings per common share $ 4.42
$ 6.03
$ 6.36
$ 6.09
$ 5.20
Diluted earnings per common share $ 4.34
$ 5.91
$ 6.25
$ 5.99
$ 5.11
Basic weighted average common
shares outstanding 98.8
84.8
90.2
95.7
100.0
Diluted weighted average common
shares outstanding 100.6
86.4
91.8
97.4
101.8

Cash and cash equivalents, and
short-term investments $ 716.4
$ 580.0
$ 404.0
$ 466.8
$ 159.3
Goodwill and intangible assets, net 9,551.2
4,575.2
4,594.8
4,569.4
4,302.5
Total assets 14,221.7
7,301.8
6,965.9
6,795.0
6,111.8
Long-term obligations (g) 6,417.0
3,029.8
3,000.4
2,655.0
2,221.0
Total shareholders' equity 4,944.4
2,820.5
2,491.3
2,717.4
2,503.5
(a) During 2015, the Company recorded net restructuring charges of $113.9. The charges were comprised of $59.2 in severance and other personnel
costs and $55.8 in facility-related costs primarily associated with facility closures and general integration initiatives. These charges were offset
by the reversal of previously established reserves of $1.1 in unused facility-related costs.
(b) During 2014, the Company recorded net restructuring charges of $17.8. The charges were comprised of $10.5 in severance and other personnel
costs and $8.4 in facility-related costs primarily associated with facility closures and general integration initiatives. These charges were offset
by the reversal of previously established reserves of $0.4 in unused severance and $0.7 in unused facility-related costs.
(c) During 2013, the Company recorded net restructuring charges of $21.8. The charges were comprised of $15.4 in severance and other personnel
costs and $9.5 in facility-related costs primarily associated with facility closures and general integration initiatives. These charges were offset
by the reversal of previously established reserves of $0.7 in unused severance and $2.4 in unused facility-related costs.
(d) During 2012, the Company recorded net restructuring charges of $25.3. The charges were comprised of $16.2 in severance and other personnel
costs and $19.6 in facility-related costs primarily associated with the ongoing integration activities of Cellmark Forensics, Inc. (formerly Orchid
Cellmark, Inc.) and the Integrated Genetics business (formerly Genzyme Genetics) and costs associated with the previously announced
termination of an executive vice president. These charges were offset by the reversal of previously established reserves of $6.3 in unused
severance and $4.2 in unused facility-related costs. As part of the Clearstone integration, the Company also recorded a $6.9 loss on the disposal
of one of its European subsidiaries in Other, net under Other income (expenses) during 2012. In addition, the Company recorded $6.2 in
accelerated amortization relating to the termination of a licensing agreement.
(e) During 2011, the Company recorded net restructuring charges of $44.6. Of this amount, $27.4 related to severance and other personnel costs,
and $22.0 primarily related to facility-related costs associated with the ongoing integration
47